Avenue Therapeutics (NASDAQ:ATXI) posted its quarterly earnings data on Wednesday. The company reported ($0.43) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.05, Bloomberg Earnings reports.
ATXI traded up $0.09 during trading on Thursday, reaching $6.00. 176 shares of the stock traded hands, compared to its average volume of 13,701. The stock has a market capitalization of $99.36 million, a PE ratio of -2.86 and a beta of -0.41. The company has a 50-day simple moving average of $6.04. Avenue Therapeutics has a 12 month low of $2.08 and a 12 month high of $7.98.
In related news, Director Neil Herskowitz acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were bought at an average price of $5.86 per share, with a total value of $29,300.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Joseph Walter Vazzano sold 4,688 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $5.59, for a total transaction of $26,205.92. Following the transaction, the chief financial officer now directly owns 59,038 shares in the company, valued at approximately $330,022.42. The disclosure for this sale can be found here. Corporate insiders own 5.00% of the company’s stock.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
Further Reading: Street Name
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.